To detect mutations or polymorphisms at codons 80, 173, 180, 181, 184, 194, 202, 204, 236 and 250 of the HBV polymerase gene. Mutations at these positions may confer resistance of HBV to antiviral drugs such as lamivudine, telbivudine, emtricitabine, adefovir, tenofovir and entecavir.
5 mL blood in sterile EDTA container or 2 mL plasma (separated from EDTA-treated or whole blood) in sterile screw-capped polypropylene tube. Samples should be collected from patients positive for HBV DNA with a viral load of >10,000 copies/mL or >2,000 IU/mL.
Refrigerate sample until transfer to laboratory. Do not freeze. Send sample at 2 - 8°C (with an ice-pack). Sample must reach the laboratory within 24 hours after collection.
Reverse hybridization line probe assay using INNO-LiPA HBV Multi-DR (Fujirebio Europe).
Wild, Mutant or Coexistence of Wild and Mutant type detected. The mutation will be described.
2 - 15 days
31 Dec 2013 11:30 AM
Indications: Indications for testing has been last updated on 1.1.14.
Method: Method has been last updated on 1.1.14.